CAMBRIDGE, Mass. AND SAN DIEGO – (BUSINESS WIRE) – Harvard University and National Resilience, Inc. (Resilience), a manufacturing and technology company, have established a five-year research and development partnership with a $ 30 million commitment from Resilience aimed at developing complex drugs, including biologics, vaccines, acids, and cell and gene therapies.
Under the alliance agreement coordinated by Harvard’s Office of Technology Development (OTD), Resilience will fund faculty-initiated research focused on certain novel biofabrication and therapeutic technologies pioneered in university labs. The alliance also anticipates that these Harvard innovations may be commercially promoted by startups formed by Resilience expressly to drive these technologies into clinical development and commercialization.
An initial technology platform for incubation has already been identified under the alliance, with promising applications in skeletal muscle disorders. In the Harvard laboratory of Lee Rubin, PhD, professor of stem cells and regenerative biology, researchers have developed a medium to grow millions of cells. in vitro that behave like skeletal muscle stem cells (satellite cells), conserving their regenerative potential, for use in possible cell therapies. Resilience is now funding ongoing lab work on the platform, with the goal of further validating it, in a project led by scientist Feodor Price, PhD.
Meanwhile, Resilience has formed an entity called Circle Therapeutics, anticipating that Circle may carry forward the technology under license.
“For six decades since the discovery of the satellite cell, it has not been possible to expand the therapeutic number of satellite cells in vitro, until we made real breakthroughs at Harvard, ”said Rubin. “We are really excited about the possible therapeutic impact of our innovations. ”
“Our mission at Resilience is to make a new generation of complex medications, such as curative gene therapies, life-saving vaccines, and immune-boosting cellular therapies, more accessible to people in need, ”said Rahul Singhvi, Sc. D, Executive Director of Resilience. “Today’s biofabrication processes pose significant obstacles to making these drugs rapidly and on a large scale, so we are excited to be working with Harvard researchers to identify and develop the technologies needed to make this future a reality. ”
“Rubin Lab’s platform to expand and maintain in vitro derived satellite cells could lead to transformative cell therapies, ”said Vivian Berlin, PhD, Executive Director of HMS, at Harvard OTD, who leads OTD’s Corporate Alliances team. “With the prior support of the Blavatnik Biomedical Accelerator, the team has convincingly demonstrated the clinical relevance of this work. Now, with Resilience’s focused funding and expertise in complex drug development, we hope to put it on a clear path to benefit patients. ”
Going forward, Resilience and Harvard will jointly issue a call for proposals to identify additional research projects to be funded at Harvard. Under the terms of the alliance, Resilience will receive an option to license technologies arising from funded projects.
“This research alliance with Resilience will help support biomedical innovation at Harvard, ”said Isaac Kohlberg, Harvard Director of Technology Development and Senior Associate Chancellor. “By collaborating to advance Harvard science and place emerging technologies with dedicated startups, we can provide another valuable source of support and industry expertise to Harvard School translational biomedical researchers in their quest to improve human health. ”
About the Harvard Office of Technology Development
The Harvard Office of Technological Development (OTD) promotes the public good by fostering innovation and translating new inventions made at Harvard University into useful products that are available and beneficial to society. Our integrated approach to technology development encompasses sponsored research and corporate partnerships, intellectual property management, and technology commercialization through business start-ups and licensing. More than 90 startups launched to commercialize Harvard technologies in the past 5 years, collectively raising more than $ 4.5 billion in funding. To further close the academic-industrial development gap, Harvard OTD administers the Blavatnik Biomedical Accelerator and the Engineering and Physical Sciences Accelerator. For more information, visit https://otd.harvard.edu.
Resilience is a technology and manufacturing company dedicated to expanding access to complex drugs and protecting biopharmaceutical supply chains from disruption. Founded in 2020, the company is building a sustainable network of high-tech end-to-end manufacturing solutions with the goal of ensuring that the medicines of today and tomorrow can be manufactured quickly, safely and at scale. Resilience seeks to offer flexible and adaptable facilities and regulatory capabilities to serve partners of all sizes. By continually advancing the science of biopharmaceutical manufacturing and development, Resilience aims to free up partners to focus on discoveries that improve the lives of patients. For more information, visit www.Resilience.com.